Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Antimicrobial Agents and Chemotherapy|June 23, 2025
Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitroRhodri Harfoot, Blair Lawley, Leonor C Hernández, et al.
The New Zealand Medical Journal|June 21, 2022
Clinical features of patients hospitalised with COVID-19 from February to October 2020, during the early waves of the pandemic in New ZealandAliya Bryce, Lydia Foley, Juliette Phillipson, et al.
Archives of Microbiology|October 18, 2025
Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infectionsDhammika Leshan Wannigama, Jingping Shao, Hongya Sun, et al.
Bioactive Materials|April 7, 2022
Antibiofilm and immunomodulatory resorbable nanofibrous filing for dental pulp regenerative proceduresMauricio Gonçalves da Costa Sousa, Gabriela Conceição de Almeida, Danilo César Martins Mota, et al.
IJID Regions|August 26, 2024
COVID-19-related hospitalizations among Aotearoa, New Zealand children during the Omicron era of SARS-CoV-2Amanda Taylor, Emma J Best, Tony Walls, et al.
Internal Medicine Journal|June 21, 2025
Variation in clinical presentation, complications and outcomes for Māori and Pacific peoples among hospitalised adults with COVID-19 in 2022, Aotearoa New ZealandMichael J Maze, Haylea Rodgers, Jonathan Williman, et al.
IJID Regions|September 16, 2024
Evaluation of risk prediction scores for adults hospitalized with COVID-19 in a highly-vaccinated population, Aotearoa New Zealand 2022Michael James Maze, Jonathan Williman, Rebekah Anstey, et al.
Scientific Reports|November 23, 2024
Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniaeAye Mya Sithu Shein, Dhammika Leshan Wannigama, Cameron Hurst, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 4, 2024
Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infectionAye Mya Sithu Shein, Dhammika Leshan Wannigama, Cameron Hurst, et al.
NEJM Evidence|February 6, 2024
A Randomized Trial of Nafamostat for Covid-19Susan C Morpeth, Balasubramanian Venkatesh, James A Totterdell, et al.
Pageof 18